Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy

Within-group comparison: There were no significant differences in best-corrected visual acuity (BCVA), central foveal thickness (CFT), and microaneurysms in the laser group before and after treatment, but there were statistically significant improvements in the combination group. After the treatment, the BCVA of the patients in the combination group was 0.44 ± 0.17, which was significantly better than 0.70 ± 0.18 before treatment; the CFT after treatment was 266.51 ± 33.28 μm, which was significantly lower than 382.37 ± 54.03 μm at baseline; the MA after treatment was 56.12 ± 23.29, which was significantly lower than 121.44 ± 40.35. There was a statistically significant decrease in hard exudates area in both two groups before and after treatment. Comparison between groups: The difference in BCVA, CFT, MA and between the two groups was statistically significant (all P < 0.05), and the area of retinal neovascularization between the two groups was no significant difference, but decreased more rapidly in the combination group than that in the laser group.